Andrew Booth

CIK: 0001834411

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ABCL

AbCellera Biologics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ABCL
AbCellera Biologics Inc.
Aug 14, 2026
Purchase(P)
Direct
37.2K shares at avg. $10.32$384K
ABCL
AbCellera Biologics Inc.
Jun 3, 2026
Exercise(M)
Direct
250K shares at avg. $0.19$48K
ABCL
AbCellera Biologics Inc.
Feb 27, 2026
Purchase(P)
Direct
42.6K shares at avg. $3.42$146K
ABCL
AbCellera Biologics Inc.
Jan 1, 2026
Award(A)
Share option (right to buy)
Direct
808.9K shares-
ABCL
AbCellera Biologics Inc.
Jan 1, 2025
Award(A)
Share option (right to buy)
Direct
1.4M shares-

		Type	Shares	Price		Ownership
Aug 14, 2026	ABCL AbCellera Biologics Inc.	Purchase(P)	37,200	$10.32	$383,904	Direct
Jun 3, 2026	ABCL AbCellera Biologics Inc.	Exercise(M)	250,000	$0.19	$47,500	Direct
Feb 27, 2026	ABCL AbCellera Biologics Inc.	Purchase(P)	42,600	$3.42	$145,692	Direct
Jan 1, 2026	ABCL AbCellera Biologics Inc.	Award(A) Share option (right to buy)	808,898	-	-	Direct
Jan 1, 2025	ABCL AbCellera Biologics Inc.	Award(A) Share option (right to buy)	1,352,054	-	-	Direct

1-5 of 5 transactions

About Booth Andrew

Booth Andrew (SEC CIK 0001834411) files insider reports with the SEC as Chief Financial Officer of AbCellera Biologics Inc. (ABCL).

Signal8 holds 5 ownership filings by Booth Andrew, all Form 4s, filed between Jan 3, 2025 and Aug 14, 2026. Those filings report 5 transactions, from Jan 1, 2025 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Booth Andrew's filings is in VANCOUVER.

Recent filings by Booth Andrew

Aug 14, 2026: Open-market purchase of ABCL shares (Form 4, code P).
Jun 3, 2026: Option exercise of ABCL shares (Form 4, code M).
Feb 27, 2026: Open-market purchase of ABCL shares (Form 4, code P).
Jan 1, 2026: Grant or award of ABCL derivative securities (Form 4, code A).
Jan 1, 2025: Grant or award of ABCL derivative securities (Form 4, code A).

Other insiders filing for AbCellera Biologics Inc. (ABCL)

Hayden Michael R, Director
Montalbano John S., Director
Seely Lynn, Director
Sandor Victor, Director
Quake Stephen, Director
Thermopylae Holdings Ltd., 10% Owner

How to read Form 4 transaction codes